BMRN vs ETON
BMRN: BioMarin is a biotechnology leader dedicated to transforming the lives of patients with rare, genetically defined diseases through innovative, category-defining medicines. ETON: Eton Pharmaceuticals is a specialty drug company dedicated to acquiring and commercializing a diverse portfolio of therapies for rare diseases.
Side-by-side fundamentals
| Metric | BMRN | ETON | Edge |
|---|---|---|---|
| Price as of 2026-10-21 close | $55.21 | $49.30 | |
| Market cap | $10.7B | $1.4B | |
| P/E as of 2026-10-21 | 145.29 | n/a | |
| Net margin FY2025, SEC XBRL | +10.8% | -5.8% | BMRN higher |
| Gross margin FY2025, SEC XBRL | n/a | +53.5% | |
| Operating margin FY2025, SEC XBRL | +12.7% | -1.1% | BMRN higher |
| ROE FY2025, SEC XBRL | +5.7% | -17.6% | BMRN higher |
| ROA FY2025, SEC XBRL | +4.6% | -5.0% | BMRN higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-30 | 0.66 | 0.60 | ETON lower |
| Revenue growth (YoY) FY2025, SEC XBRL | +12.9% | +104.9% | ETON higher |
| Revenue CAGR (3y) SEC XBRL | +15.4% | +55.5% | ETON higher |
| Dividend streak (yrs) SEC XBRL | 0 | 0 | Tie |
| Beta as of 2026-09-03 | 0.62 | 0.82 | |
| 1-year return as of 2026-10-21 close | +2.6% | +165.8% | ETON higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.